2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with transforming growth factor beta in 1 studies
| Studies (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Trials (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Recent Studies (post-2010) (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 85 | 0 | 62 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KH; Lee, DH; Moon, YS; Park, JG | 1 |
1 other study(ies) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and transforming growth factor beta
| Article | Year |
|---|---|
Reversine increases the plasticity of lineage-committed preadipocytes to osteogenesis by inhibiting adipogenesis through induction of TGF-β pathway in vitro.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Apoptosis; Cell Dedifferentiation; Cell Lineage; Cell Survival; Cell Transdifferentiation; Humans; Mesenchymal Stem Cells; Mice; Morpholines; Osteogenesis; Purines; Signal Transduction; Transforming Growth Factor beta | 2014 |